Business Wire

PA-IDEMIA/UNISYS

3.6.2020 12:50:07 CEST | Business Wire | Press release

Share
Australian Department of Home Affairs’ New Biometric System Goes Live Using Unisys Stealth(identity)™ and IDEMIA Biometrics

Unisys Corporation (NYSE: UIS) and IDEMIA today announced that the Australian Department of Home Affairs’ new Enterprise Biometric Identification Services (EBIS) system has gone live. EBIS is based on the Unisys Stealth(identity)™ multi-factor identity management and authentication solution and, using IDEMIA’s facial and fingerprint recognition algorithms, is one of the world’s most accurate biometric identity management systems used for visa and border processing to secure Australia’s’ borders and facilitate the flow of legitimate travellers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005403/en/

EBIS will be used by the department to match the facial images and fingerprints of people including those wishing to travel to Australia such as visa applicants and the facial images for citizenship applicants. The system simultaneously facilitates the processing of legitimate travellers and is designed to support anticipated growth in visa applications, border clearances and applications for citizenship over the next 10 years.

In 2019 there was a record annual 9.5 million visitors to Australia, 3.9 million more than 10 years earlier and 220 300 more than the previous year1 . To facilitate travellers’ journeys, border clearance staff need to efficiently verify the identities of travellers and confirm they are who they say they are to prevent delays, avoid queues and improve the overall experience for travellers. In the future, EBIS will provide the capability to quickly flag people who may be crossing the border with fraudulent identities.

Unisys designed and implemented the system within 18 months of signing the contract with the department. EBIS is based on the Stealth(identity) multi-factor identity management and authentication solution, which supports face, finger, iris and voice recognition. It is a robust solution designed for high-volume (more than 100,000 transactions daily) and large-scale galleries (more than 100 million records). Stealth(identity) provides the core biometric identity management functionality of EBIS including the user interface, workflows, business rules, identity data and record linking and auditing functionality. EBIS replaces the previous biometrics matching system that was also provided and supported by Unisys for the last 12 years.

Rick Mayhew, vice president and general manager, Unisys Asia Pacific said: “The long term growth in the volume of travellers that will hopefully return after COVID-19, as well as the increased risk of potential terrorist or fraudulent activity, means that effective border security is more important than ever. EBIS provides Home Affairs with greater confidence in verifying an individual’s identity for efficient and early detection of criminals and persons of national security concern who change names and obtain passports using false identities. We have worked closely with the department and our partner IDEMIA, the global leader in Augmented Identity, to deliver one of the world’s leading solutions to help protect Australia’s borders and national assets.”

The core of EBIS’ fingerprint and facial biometric matching solution uses industry-leading biometric matching algorithms from IDEMIA to quickly and accurately match fingerprints and facial images.

IDEMIA’s flagship product Multi Biometric Search Services (MBSS) is a multi-biometric engine that uses face and fingerprint matching algorithms. This product combines high scalability (over 1 billion identities possible) with high availability, which is necessary for mission-critical systems, integrated within IDEMIA’s world-leading biometric algorithms. The product can also include other modalities such as iris recognition, where required.

Tim Ferris, President of IDEMIA Asia Pacific and Senior Vice President for Public Security and Identity, added: “We are thrilled to provide the biometric engine that powers the EBIS solution. This is the continuation of years of IDEMIA’s engagement in the Australian Borders ecosystem. The combined strengths of IDEMIA behind Unisys provide the Department of Home Affairs with a flagship platform to secure the border now and into the future.”

Unisys has extensive experience supporting government departments and agencies in Australia and around the world. More than 240 government agencies worldwide use Unisys solutions. For more information on Unisys' Public Sector solutions, visit http://www.unisys.com.au/industries/government/public-sector .

1 – Australian Bureau of Statistics -
https://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/3401.0Main%20Features13Mar%202020

About Unisys
Unisys is a global information technology company that builds high-performance, security-centric solutions for the most demanding businesses and governments. Unisys offerings include security software and services; digital transformation and workplace services; industry applications and services; and innovative software operating environments for high-intensity enterprise computing. For more information on how Unisys builds better outcomes securely for its clients across the Government, Financial Services and Commercial markets, visit www.unisys.com.au . Follow Unisys on Twitter and LinkedIn .

###

Unisys and other Unisys products and services mentioned herein, as well as their respective logos, are trademarks or registered trademarks of Unisys Corporation. Any other brand or product referenced herein is acknowledged to be a trademark or registered trademark of its respective holder.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release

Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'

SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release

Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release

ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release

$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye